

Chorea, psychosis, acanthocytosis, and prolonged survival associated with *ELAC2* mutations

Martin Paucar, MD, PhD, Aleksandra Pajak, PhD, Christoph Freyer, PhD, Åsa Bergendal, PhD, Margit Döry, MLS, José Miguel Laffita-Mesa, PhD, Henrik Stranneheim, PhD, Kristina Lagerstedt-Robinson, PhD, Irina Savitcheva, MD, Ruth H. Walker, MB, ChB, PhD, Anna Wedell, MD, PhD, Anna Wredenberg, MD, PhD, and Per Svenningsson, MD

Correspondence

Dr. Paucar
martin.paucar-arce@sl.se

Neurology® 2018;91:710-712. doi:10.1212/WNL.0000000000006320

Biallelic mutations in the *elaC* ribonuclease Z 2 (*ELAC2*) gene cause a rare mitochondrial disease, the main features of which are hypertrophic cardiomyopathy, delayed psychomotor development, and usually death during childhood.¹ Only 20 families have been reported with this syndrome.¹⁻³ Neither movement disorders nor psychotic features have been described as part of the spectrum of *ELAC2* mutations. We describe a patient with a complex hyperkinetic syndrome and acanthocytosis, harboring biallelic *ELAC2* mutations.

MORE ONLINE

▶ Video

Case description

An Assyrian 69-year-old woman born in Turkey was evaluated at our center for a slowly progressive Huntingtonian disorder. Family history was negative. The patient came to Sweden at age 33; she never went to school and learned only a few Swedish words, and could perform simple transactions. She had type 2 diabetes mellitus, bilateral sensorineural hearing loss requiring aids since age 58, and a follicular thyroid tumor, and is a silent carrier of α -thalassemia (table e-1; doi.org/10.5061/dryad.j6s420k).

At age 52 years, the patient developed short memory impairment and increasing difficulties managing activities of daily living. Four years later, she reported olfactory hallucinations and became obsessed with cleaning and doing laundry to remove the perceived foul smells. Perioral movements were documented during an emergency room visit at age 56 for psychiatric issues, and were noted by her family to have been present for many years, predating treatment with aripiprazole. The olfactory hallucinations became so severe that she tried to commit suicide by setting her apartment on fire at age 58. This resulted in admission to a psychiatric unit for a year and treatment with aripiprazole. At age 61, worsened gait, balance, and involuntary movements were evident. For the last 3 years, she has required a walker and reports numbness in her calves. She has lost weight, but there is no evidence of feeding dystonia or dysphagia. Recently, she has become fecally incontinent.

On examination, the patient had chorea in the feet and perioral area, dystonic posturing in the hands and reduced arm movements, a waddling gait, bradykinesia, apraxia, and atrophy of the hand muscles (video 1). A simplified psychometric evaluation demonstrated significant deficits in several domains (table e-2). EEG performed twice was normal; neurophysiologic studies revealed a sensorimotor demyelinating polyneuropathy and myopathy. Muscle biopsy revealed both cytochrome oxidase (COX)-negative and ragged-red fibers. Brain MRI demonstrated atrophy in the left periorolandic frontal and temporal cortex, while FDG-PET showed reduced bilateral hypometabolism in these regions and in the insular cortex, more pronounced

From Karolinska University Hospital (M.P., A.P., C.F., M.D., J.L.-M., H.S., K.L., I.S., A. Wedell, A. Wredenberg, P.S.); Karolinska Institutet (M.P., A.P., C.F., Å.B., K.L., A. Wedell, A. Wredenberg, P.S.), Stockholm, Sweden; James J. Peters Veterans Medical Affairs Center (R.H.W.), Bronx; and Mount Sinai School of Medicine (R.H.W.), New York, NY.

Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article. The Article Processing Charge was funded by the authors.

The Article Processing Charge was funded by Swedish Research Council.

This is an open access article distributed under the terms of the Creative Commons Attribution License 4.0 (CC BY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

on the left side (figures e-1 and e-2; doi.org/10.5061/dryad.j6s420k). An incidental aneurysm in the anterior communicating artery was found and treated conservatively; there was no evidence of brain calcifications on CT scans. Huntington disease (HD) and other HD phenocopies were ruled out (appendix; doi.org/10.5061/dryad.j6s420k). Acanthocytes were found on wet blood smears (figure e-3; doi.org/10.5061/dryad.j6s420k). Whole exome sequencing revealed compound heterozygous variants c.394G>A (p.Gly132Arg) and c.1040C>T (p.Ser347Phe) in the *ELAC2* gene (figure e-4; doi.org/10.5061/dryad.j6s420k). ECG was normal but repeated echocardiography demonstrated stable mild ventricular septum hypertrophy without evidence of pump failure. Although we did not find any evidence of respiratory chain defect in the muscle biopsy, the patient's fibroblasts revealed accumulation of unprocessed mitochondrial transcripts but normal steady-state levels of mitochondrial mRNAs and tRNAs (figure 1, A and B). These fibroblasts showed severe growth impairment when using galactose as energy source (figure 1C). Treatment with coenzyme Q10 has been started and regular echocardiography is planned.


Discussion

This case demonstrates that *ELAC2* mutations are not exclusively confined to a lethal pediatric cardiomyopathy but can also be associated with symptoms and laboratory findings suggestive of a neuroacanthocytosis syndrome. Most patients with biallelic *ELAC2* mutations reported to date have died during early infancy. In a Saudi cohort of 16 patients

harboring the homozygous c.460T>C (p.Phe154Leu) mutation, the mean survival was 4 months.³ This dire prognosis makes the prolonged survival of our case remarkable. Apart from our patient, the oldest surviving patient is a 19-year-old patient with severe developmental delay and inability to walk.² There was no dysmorphism or microcephaly, as have been reported with *ELAC2* mutations.^{1,2} Accumulation of unprocessed mitochondrial transcripts and impaired fibroblast growth on galactose support pathogenicity for the *ELAC2* variants we report. Other mitochondrial diseases associated with chorea include Leigh syndrome and mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS),^{4,5} although these are typically associated with basal ganglia lesions on imaging. Our patient had myopathy, hearing loss, diabetes, and polyneuropathy, which are typical of mitochondrial disease. Even though perioral chorea antedated treatment with aripiprazole, it is not possible to rule out that bradykinesia, dystonic hand posturing, and chorea in the trunk and feet may be side effects of this treatment. The radiologic abnormalities (unilateral frontal and temporal atrophy) and bilateral hypometabolism in the operculum and insula are also new findings for *ELAC2* mutations. Interestingly, injuries in the insula have been reported in association with olfactory hallucinations.⁶

The presence of acanthocytosis, in addition to myopathy, polyneuropathy, and chorea, suggests a neuroacanthocytosis syndrome (i.e., chorea-acanthocytosis and McLeod syndrome, which were excluded in this case); dilated, but not hypertrophic, cardiomyopathy is typical in McLeod syndrome.⁷ One case of MELAS has been reported to be

Figure Northern blot analysis of total RNA extractions from primary fibroblasts



(A) Steady-state levels of mitochondrial mRNAs. 18S rRNA was used as loading control. Controls: C1 and C2, patient: ELAC2mut. (B) Steady-state levels of mitochondrial tRNA-tryptophane (mt-tW) and the nuclear-encoded tRNA-cysteine (cyt-tC) from control (C1, C2) and patient fibroblasts, grown for 14 days on galactose-containing medium. *Unprocessed mitochondrial transcript, arrow = tRNA. (C) Growth curves of control and patient fibroblasts grown on galactose. Experiments were performed in triplicates. Error bars indicate standard error.

associated with acanthocytosis.⁸ We propose that *ELAC2* should be added to the list of potential causes of neuroacanthocytosis syndromes.

Author contributions

M. Paucar, A. Wredenberg, R.H. Walker, K. Lagerstedt-Robinson, J. Laffita, A. Wedell, P. Svenningsson: study concept, data collection, writing of the manuscript. M. Paucar: wrote the first draft. A. Wedell, A. Wredenberg, C. Freyer, A. Pajak, H. Stranneheim, and K. Lagerstedt-Robinson: performed the assessment of mitochondrial function and genetic analysis. I. Savitcheva: contributed imaging data. Å. Bergendal: performed the cognitive evaluation. R.H. Walker, A. Wredenberg, A. Wedell, C. Freyer, Å. Bergendal, I. Savitcheva, J. Laffita, P. Svenningsson: editing of the manuscript.

Acknowledgment

The authors thank the patient and her son for participation; Dr. H. Salim for referring the patient; Dr. Inger Nennesmo for the neuropathologic investigation; and Nicole Lesko for assistance with the genetic data.

Study funding

M. Paucar's research was supported by the Stockholm County Council. A. Wedell's research is supported by the Swedish Research Council (2016-01082), the Stockholm County Council (20170022), and the Knut & Alice Wallenberg Foundation (KAW 2013.0026 and KAW 2014.0293). A. Wredenberg is a Ragnar Söderberg Fellow in Medicine (M77/13); her research is supported by the Swedish Research Council AW (2016-02179), Stockholm County Council, and

Knut & Alice Wallenberg Foundation. P. Svenningsson is a Wallenberg Clinical Scholar; his research is supported by the Stockholm County Council (ALF).

Disclosure

The authors report no disclosures relevant to the manuscript. Go to Neurology.org/N for full disclosures.

Publication history

Previously published at bioRxiv doi: 10.1101/244848. Received by *Neurology: Neuroimmunology & Neuroinflammation* February 8, 2018. Accepted in final form July 19, 2018.

References

1. Haack TB, Kopajtic R, Freisinger P, et al. *ELAC2* mutations cause a mitochondrial RNA processing defect associated with hypertrophic cardiomyopathy. *Am J Hum Genet* 2013;93:211–223.
2. Akawi NA, Ben-Salem S, Hertecant J, et al. A homozygous splicing mutation in *ELAC2* suggests phenotypic variability including intellectual disability with minimal cardiac involvement. *Orphanet J Rare Dis* 2016;11:139.
3. Shinwari ZMA, Almesned A, Alakhfash A, et al. The phenotype and outcome of infantile cardiomyopathy caused by a homozygous *ELAC2* mutation. *Cardiology* 2017;137:188–192.
4. Singmaneesakulchai S, Limotai N, Jagota P, Bhidayasiri R. Expanding spectrum of abnormal movements in MELAS syndrome (mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes). *Mov Disord* 2012;27:1495–1497.
5. Rahman S, Thorburn D. Nuclear gene-encoded Leigh syndrome overview. In: Adam MP, Ardinger HH, Pagon RA, et al, eds. *GeneReviews*[®] [Internet]. Seattle: University of Washington; 1993.
6. Beume LA, Klinger A, Reinhard M, Niesen WD. Olfactory hallucinations as primary symptom for ischemia in the right posterior insula. *J Neurol Sci* 2015;354:138–139.
7. Jung HH, Danek A, Walker RH, Frey BM, Gassner C. McLeod neuroacanthocytosis syndrome. In: Adam MP, Ardinger HH, Pagon RA, et al, editors. *GeneReviews*[®]. Seattle: University of Washington; 1993.
8. Mukoyama M, Kazui H, Sunohara N, Yoshida M, Nonaka I, Satoyoshi E. Mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes with acanthocytosis: a clinicopathological study of a unique case. *J Neurol* 1986;233:228–232.

Visit the *Neurology*[®] Resident & Fellow Website

Click on Residents & Fellows tab at Neurology.org.

Now offering:

- *Neurology*[®] Resident & Fellow Editorial team information
- “Search by subcategory” option
- E-pearl of the Week
- RSS Feeds
- Direct links to Continuum[®], Career Planning, and AAN Resident & Fellow pages
- Recently published Resident & Fellow articles
- Podcast descriptions

 Find *Neurology*[®] Residents & Fellows Section on Facebook: <http://tinyurl.com/o8ahsys>

 Follow *Neurology*[®] on Twitter: <http://twitter.com/GreenJournal>

Neurology®

Chorea, psychosis, acanthocytosis, and prolonged survival associated with *ELAC2* mutations

Martin Paucar, Aleksandra Pajak, Christoph Freyer, et al.
Neurology 2018;91:710-712 Published Online before print September 14, 2018
DOI 10.1212/WNL.0000000000006320

This information is current as of September 14, 2018

Updated Information & Services	including high resolution figures, can be found at: http://n.neurology.org/content/91/15/710.full
References	This article cites 6 articles, 0 of which you can access for free at: http://n.neurology.org/content/91/15/710.full#ref-list-1
Subspecialty Collections	This article, along with others on similar topics, appears in the following collection(s): All Genetics http://n.neurology.org/cgi/collection/all_genetics All Movement Disorders http://n.neurology.org/cgi/collection/all_movement_disorders Chorea http://n.neurology.org/cgi/collection/chorea Mitochondrial disorders http://n.neurology.org/cgi/collection/mitochondrial_disorders
Permissions & Licensing	Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: http://www.neurology.org/about/about_the_journal#permissions
Reprints	Information about ordering reprints can be found online: http://n.neurology.org/subscribers/advertise

Neurology® is the official journal of the American Academy of Neurology. Published continuously since 1951, it is now a weekly with 48 issues per year. Copyright Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.. All rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X.

